#United States #healthcare #Stamford #Olympus Partners #PAI Pharma

Olympus Partners Acquires PAI Pharma: A Game Changer in Generic Oral Liquids

In a strategic move that underscores its commitment to expanding its healthcare portfolio, Olympus Partners has announced its acquisition of PAI Pharma, a leading name in the development, manufacture, and distribution of generic oral liquids in the United States. Established over 50 years ago, PAI Pharma has built a robust reputation for offering a wide range of generic oral liquid medicines in convenient ready-to-dose formats, addressing the diverse needs of retail chains, independent pharmacies, hospitals, long-term care facilities, and even government agencies.

This acquisition is significant not only for Olympus but also for the healthcare landscape as a whole. With PAI Pharma's expansive portfolio, which is considered the broadest in the industry concerning oral liquid generics, patients will benefit from improved access to essential medications. The facilities in Parsippany, New Jersey, and two manufacturing campuses located in Greenville, South Carolina, ensure that PAI can continue meeting the healthcare demands across the country while maintaining high production standards.

As highlighted by Griffin Barstis, a partner at Olympus, PAI has consistently demonstrated innovation in producing better-targeted suspensions and oral solutions, setting them apart in a competitive market. Under Olypmus’s stewardship, PAI looks forward to enhanced operational efficiencies and scaling their production capabilities significantly.

Kurt Orlofski, the CEO of PAI Pharma, expressed enthusiasm about this new partnership, acknowledging Olympus's extensive experience and success in private equity. “Our collaboration with Olympus Partners comes at a pivotal time in our evolution as a company,” he stated. “With their strategic guidance and financial strength, we are poised to accelerate our growth trajectory and expand our product offerings.”

Founded in 1988, Olympus Partners has primarily focused on providing equity capital for middle-market management buyouts and growth initiatives. The firm manages assets exceeding $11 billion, primarily on behalf of corporate pension funds, endowments, and state-sponsored retirement programs. Their investment philosophy revolves around long-term growth, and they have a notable presence across various sectors, including healthcare, consumer products, and financial services.

The acquisition comes at a time when the healthcare industry is facing increased pressure to lower prescription costs and improve access to necessary medications. Olympus's strategic acquisition of PAI Pharma showcases their commitment to enhancing healthcare delivery while addressing the needs of millions of patients relying on affordable generics.

As the healthcare landscape continues to evolve, partnerships like that of Olympus and PAI Pharma will play a crucial role in ensuring that quality medications are within reach for all, affirming the importance of accessibility in today’s health system. As they embark on this new chapter together, both companies are well-positioned to lead in the generic oral liquid segment, promising a brighter future for patients and healthcare providers alike.